The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Anokhin P.K.

Nationa Research Center on Addiction — The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology

Veretinskaya A.G.

Nationa Research Center on Addiction — The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology

Pavshintsev V.V.

Lomonosov Moscow State University

Shamakina I.Yu.

Nationa Research Center on Addiction — The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology

The effect of the dopamine D2 receptor agonist cabergoline on the content of catecholamines and expression of BDNF mRNA in the rat midbrain and hypothalamus

Authors:

Anokhin P.K., Veretinskaya A.G., Pavshintsev V.V., Shamakina I.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(11): 54‑59

DOI: 10.17116/jnevro201911911154

Read: 9441 times

Contact the author
Table of contents

THE EFFECT OF THE DOPAMINE D2 RECEPTOR AGONIST CABERGOLINE ON THE CONTENT OF CATECHOLAMINES AND EXPRESSION OF BDNF MRNA IN THE RAT MIDBRAIN AND HYPOTHALAMUS
THE EFFECT OF THE DOPAMINE D2 RECEPTOR AGONIST CABERGOLINE ON THE CONTENT OF CATECHOLAMINES AND EXPRESSION OF BDNF MRNA IN THE RAT MIDBRAIN AND HYPOTHALAMUS

To cite this article:

Anokhin PK, Veretinskaya AG, Pavshintsev VV, Shamakina IYu. The effect of the dopamine D2 receptor agonist cabergoline on the content of catecholamines and expression of BDNF mRNA in the rat midbrain and hypothalamus. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(11):54‑59. (In Russ.)
https://doi.org/10.17116/jnevro201911911154

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Inte­rleukin-6, cortisol, and brain-derived neurotrophic factor as biomarkers of the seve­rity of traumatic brain injury and its complications in acute and long-term periods: resu­lts of a prospective study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):237-243
Effect of poly­morphic variants of genes of neurotrophic factors on the disease seve­rity and the anxiety level in patients with affe­ctive diso­rders and como­rbid alco­hol depe­ndence. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):126-131
The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cere­brovascular acci­dents. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(2):123-129
Clinical stra­tification of psoriasis phenotypes considering neuroimmune markers and asso­ciated psycho-emotional diso­rders. Russian Journal of Clinical Dermatology and Vene­reology. 2026;(2):214-217
Abstract:

OBJECTIVE

To study an effect of cabergoline on dopamine and noradrenaline concentration and BDNF mRNA level in the rat midbrain and hypothalamus.

MATERIAL AND METHODS

Twenty adult male Wistar rats were used in a single treatment paradigm: animals of the treatment group (n=10) received cabergoline (i.p., 0.5 mg/kg) and the control group (n=10) received an equivalent volume of the solvent. Quantitative analysis for the dopamine (DA) and noradrenaline (NA) was carried out using high-performance liquid chromatography (HPLC) coupled with electrochemical detection. BDNF mRNA levels were studied using quantitative RT-PCR.

RESULTS AND CONCLUSION

Cabergoline significantly increases NA concentration in the midbrain 24 hours after injection: 639.2±64.5 ng/g in the treatment group versus 398.0±66.0 ng/g in the control group (p<0.05), while mean content of DA is not significantly changed (211.4±16.3 ng/g vs 169.7±54.6 ng/g, respectively). Cabergoline does not affect hypothalamic DA and NA levels. The drug increases BDNF mRNA levels by 2-times in the midbrain, but not in the hypothalamus, 24 hours after injection.

Keywords:

dopamine
catecholamines
D2-receptors
cabergoline
BDNF

Authors:

Anokhin P.K.

Nationa Research Center on Addiction — The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology

Veretinskaya A.G.

Nationa Research Center on Addiction — The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology

Pavshintsev V.V.

Lomonosov Moscow State University

Shamakina I.Yu.

Nationa Research Center on Addiction — The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology

Received:

21.05.2019

Accepted:

31.07.2019

Close metadata

References:

  1. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson’s disease. Drugs. 2004;64(18):2125-2141. https://doi.org/10.2165/00003495-200464180-00015
  2. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011;16(3):CD006009. https://doi.org/10.1002/14651858.CD006009.pub2
  3. Feelders R, Hofland L. Medical Treatment of Cushing’s Disease. The Journal of Clinical Endocrinology & Metabolism. 2013;98(2):425-438.  https://doi.org/10.1210/jc.2012-3126
  4. Wang A, Mullan R, Lane M Hazem A, Chaithra Prasad C, Gathaiya N, Mercè Fernández-Balsells M, Bagatto A, Coto-Yglesias F, Carey J, Elraiyah TA, Erwin P, Gandhi GY, Montori V, Hassan Murad M. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1(1). https://doi.org/10.1186/2046-4053-1-33
  5. Reichmann H, Bilsing A, Ehret R, Greulich W, Schulz JB, Schwartz A, Rascol O. Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease. J Neurol. 2006;253(4):36-38.  https://doi.org/10.1007/s00415-006-4009-z
  6. Shamakina IYu, Proskuryakova TV, Shokhonova VA, Ulyanova EV, Anokhin PK, Tapabarko IE, Anokhina IP. An effect of cabergoline on alcohol consumption and DRD2 expression in the brain of rats with chronic alcohol intoxication. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(11-2):74.  https://doi.org/10.17116/jnevro201611611274-80
  7. Carnicella S, Ahmadiantehrani S, He D, Nielsen, C. K., Bartlett, SE, Janak, PH, Ron D. Cabergoline Decreases Alcohol Drinking and Seeking Behaviors Via Glial Cell Line-Derived Neurotrophic Factor. Biol Psychiatry. 2009;66(2):146-153.  https://doi.org/10.1016/j.biopsych.2008.12.022
  8. Chiba S, Numakawa T, Ninomiya M, Yoon H, Kunugi H. Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. Psychopharmacology (Berl). 2010;211(3):291-301.  https://doi.org/10.1007/s00213-010-1894-8
  9. Sivolap YuP. Treatment of anxiety disorders in alcohol abusers. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(1):34.  https://doi.org/10.17116/jnevro20181181234-38
  10. Sivolap YuP. Alcohol use disorders: current approaches to diagnosis and treatment. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(9):23.  https://doi.org/10.17116/jnevro20151159123-27
  11. Delgado PL. Depression: the case for a monoamine deficiency. The Journal of Clinical Psychiatry. 2000;61(6):7-11. 
  12. Duman R, Monteggia L. A Neurotrophic Model for Stress-Related Mood Disorders. Biol Psychiatry. 2006;59(12):1116-1127. https://doi.org/10.1016/j.biopsych.2006.02.013
  13. Björkholm C, Monteggia L. BDNF — a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72-79.  https://doi.org/10.1016/j.neuropharm.2015.10.034
  14. Shirayama Y, Chen A, Nakagawa S, Russell D, Duman R. Brain-Derived Neurotrophic Factor Produces Antidepressant Effects in Behavioral Models of Depression. The Journal of Neuroscience. 2002;22(8):3251-3261. https://doi.org/10.1523/jneurosci.22-08-03251.2002
  15. Adachi M, Barrot M, Autry A, Theobald D, Monteggia L. Selective Loss of Brain-Derived Neurotrophic Factor in the Dentate Gyrus Attenuates Antidepressant Efficacy. Biol Psychiatry. 2008;63(7):642-649.  https://doi.org/10.1016/j.biopsych.2007.09.019
  16. Rantamäki T, Hendolin P, Kankaanpää A, Mijatovic J, Piepponen P, Domenici E, Chao MV, Männistö PT, Castrén E. Pharmacologically Diverse Antidepressants Rapidly Activate Brain-Derived Neurotrophic Factor Receptor TrkB and Induce Phospholipase-Cγ Signaling Pathways in Mouse Brain. Neuropsychopharmacology. 2007;32(10):2152-2162. https://doi.org/10.1038/sj.npp.1301345
  17. Murínová J, Hlaváčová N, Chmelová M, Riečanský I. The Evidence for Altered BDNF Expression in the Brain of Rats Reared or Housed in Social Isolation: A Systematic Review. Front Behav Neurosci. 2017;11.  https://doi.org/10.3389/fnbeh.2017.00101
  18. Eisch AJ, Bolaños CA, de Wit J, Simonak RD, Pudiak CM, Barrot M. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biological Psychiatry. 2003;54(10):994-1005. https://doi.org/10.1016/s0006-3223(03)00869-2
  19. Berton O. Essential Role of BDNF in the Mesolimbic Dopamine Pathway in Social Defeat Stress. Science. 2006;311(5762):864-868.  https://doi.org/10.1126/science.1120972
  20. Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014;282:13-22.  https://doi.org/10.1016/j.neuroscience.2014.01.025
  21. Cordeira J, Frank L, Sena-Esteves M, Pothos E, Rios M. Brain-Derived Neurotrophic Factor Regulates Hedonic Feeding by Acting on the Mesolimbic Dopamine System. Journal of Neuroscience. 2010;30(7):2533-2541. https://doi.org/10.1523/jneurosci.5768-09.2010
  22. Davis MI. Ethanol-BDNF interactions: still more questions than answers. Pharmacol Ther. 2008;118(1):36-57.  https://doi.org/10.1016/j.pharmthera.2008.01.003
  23. Elpí EAM. Krstulovic (Ed.) Quantitative analysis of catecholamines and related compounds Ellis Horwood Limited, 1986 Chichester, England. pp 384. Biol Mass Spectrom. 1988;15(7):411-411.  https://doi.org/10.1002/bms.1200150709
  24. Schmittgen T, Livak K. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108. https://doi.org/10.1038/nprot.2008.73
  25. Rossetti Z, Pani L, Portas C, Gessa G. Brain dialysis provides evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. Eur J Pharmacol. 1989;163(2-3):393-395.  https://doi.org/10.1016/0014-2999(89)90214-8
  26. Galzin AM, Dubocovich ML, Langer SZ. Presynaptic inhibition by dopamine receptor agonists of noradrenergic neurotransmission in the rabbit hypothalamus. J Pharmacol Exp Ther. 1982;221:461. 
  27. Misu Y, Goshima Y, Kubo T. Biphasic actions of l-DOPA on the release of endogenous dopamine via presynaptic receptors in rat striatal slices. Neurosci Lett. 1986;72(2):194-198.  https://doi.org/10.1016/0304-3940(86)90079-0
  28. Guiard B, El Mansari M, Blier P. Cross-Talk between Dopaminergic and Noradrenergic Systems in the Rat Ventral Tegmental Area, Locus Ceruleus, and Dorsal Hippocampus. Mol Pharmacol. 2008;74(5):1463-1475. https://doi.org/10.1124/mol.108.048033
  29. Lee A, Wissekerke A, Rosin D, Lynch K. Localization ofα2c-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience. 1998;84(4):1085-1096. https://doi.org/10.1016/s0306-4522(97)00578-2
  30. Guiard B, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. International Journal of Neuropsychopharmacology. 2008;11(5):625-639.  https://doi.org/10.1017/s1461145707008383
  31. Linne´r L, Endersz H, Ohman D, Bengtsson F, Schalling M, and Svensson TH. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther. 2001;297:540-546. 
  32. Ornstein K, Milon H, McRae-Degueurce A, Alvarez C, Berger B, Warzner H. Biochemical and radioautographic evidence for dopaminergic afferents of the locus coeruleus originating in the ventral tegmental area. J Neural Transm. 1987;70(3-4):183-191.  https://doi.org/10.1007/bf01253597
  33. Yokoyama C, Okamura H, Nakajima T, Taguchi J, Ibata Y. Autoradiographic distribution of [3H]YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord. J Comp Neurol. 1994;344(1):121-136.  https://doi.org/10.1002/cne.903440109
  34. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. Journal of Neurology, Neurosurgery & Psychiatry. 2012;84(7):774-783.  https://doi.org/10.1136/jnnp-2011-301817
  35. Kokhan V, Kokhan T, Samsonova A, Fisenko V, Ustyugov A, Aliev G. The dopaminergic dysfunction and altered working memory performance of aging mice lacking gamma-synuclein gene. CNS & Neurological Disorders — Drug Targets. 2018;17.  https://doi.org/10.2174/1871527317666180726095734
  36. Kokhan V, Van’kin G, Bachurin S, Shamakina I. Differential involvement of the gamma-synuclein in cognitive abilities on the model of knockout mice. BMC Neurosci. 2013;14(1):53.  https://doi.org/10.1186/1471-2202-14-53
  37. Odaka H, Numakawa T, Adachi N, Ooshima Y, Nakajima S, Katanuma Y, Inoue T, Kunugi H. Cabergoline, Dopamine D2 Receptor Agonist, Prevents Neuronal Cell Death under Oxidative Stress via Reducing Excitotoxicity. PLoS ONE. 2014;9(6):e99271. https://doi.org/10.1371/journal.pone.0099271
  38. Salim S. Oxidative Stress and the Central Nervous System. Journal of Pharmacology and Experimental Therapeutics. 2016;360(1):201-205.  https://doi.org/10.1124/jpet.116.237503
  39. Haorah J, Ramirez SH, Floreani N, Gorantla S, Morsey B, Persidsky Y. Mechanism of alcohol-induced oxidative stress and neuronal injury. Free Radic Biol Med. 2008;45(11):1542-1550. https://doi.org/10.1016/j.freeradbiomed.2008.08.030
  40. Benarroch E. The locus ceruleus norepinephrine system: Functional organization and potential clinical significance. Neurology. 2009;73(20):1699-1704. https://doi.org/10.1212/wnl.0b013e3181c2937c
  41. Rommelfanger K, Weinshenker D, Miller G. Reduced MPTP toxicity in noradrenaline transporter knockout mice. J Neurochem. 2004;91(5):1116-1124. https://doi.org/10.1111/j.1471-4159.2004.02785.x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.